Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was...

Descripción completa

Detalles Bibliográficos
Autores principales: Krbot Skorić, Magdalena, Rogić, Dunja, Lapić, Ivana, Šegulja, Dragana, Habek, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629510/
https://www.ncbi.nlm.nih.gov/pubmed/34920248
http://dx.doi.org/10.1016/j.msard.2021.103435
_version_ 1784607221178433536
author Krbot Skorić, Magdalena
Rogić, Dunja
Lapić, Ivana
Šegulja, Dragana
Habek, Mario
author_facet Krbot Skorić, Magdalena
Rogić, Dunja
Lapić, Ivana
Šegulja, Dragana
Habek, Mario
author_sort Krbot Skorić, Magdalena
collection PubMed
description The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.
format Online
Article
Text
id pubmed-8629510
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-86295102021-11-30 Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod Krbot Skorić, Magdalena Rogić, Dunja Lapić, Ivana Šegulja, Dragana Habek, Mario Mult Scler Relat Disord Correspondence The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod. Elsevier B.V. 2022-01 2021-11-29 /pmc/articles/PMC8629510/ /pubmed/34920248 http://dx.doi.org/10.1016/j.msard.2021.103435 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Krbot Skorić, Magdalena
Rogić, Dunja
Lapić, Ivana
Šegulja, Dragana
Habek, Mario
Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
title Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
title_full Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
title_fullStr Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
title_full_unstemmed Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
title_short Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
title_sort humoral immune response to covid-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629510/
https://www.ncbi.nlm.nih.gov/pubmed/34920248
http://dx.doi.org/10.1016/j.msard.2021.103435
work_keys_str_mv AT krbotskoricmagdalena humoralimmuneresponsetocovid19vaccinesinpeoplewithsecondaryprogressivemultiplesclerosistreatedwithsiponimod
AT rogicdunja humoralimmuneresponsetocovid19vaccinesinpeoplewithsecondaryprogressivemultiplesclerosistreatedwithsiponimod
AT lapicivana humoralimmuneresponsetocovid19vaccinesinpeoplewithsecondaryprogressivemultiplesclerosistreatedwithsiponimod
AT seguljadragana humoralimmuneresponsetocovid19vaccinesinpeoplewithsecondaryprogressivemultiplesclerosistreatedwithsiponimod
AT habekmario humoralimmuneresponsetocovid19vaccinesinpeoplewithsecondaryprogressivemultiplesclerosistreatedwithsiponimod

Ejemplares similares